Aclaris Therapeutics Inc. (ACRS)
NASDAQ: ACRS
· Real-Time Price · USD
1.47
-0.06 (-3.92%)
At close: Jun 13, 2025, 3:59 PM
1.44
-2.11%
After-hours: Jun 13, 2025, 05:43 PM EDT
-3.92% (1D)
| Bid | 1.42 |
| Market Cap | 159.29M |
| Revenue (ttm) | 17.78M |
| Net Income (ttm) | -130.21M |
| EPS (ttm) | -1.59 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -2.38 |
| Analyst | Buy |
| Ask | 1.54 |
| Volume | 444,810 |
| Avg. Volume (20D) | 856,582 |
| Open | 1.50 |
| Previous Close | 1.53 |
| Day's Range | 1.47 - 1.55 |
| 52-Week Range | 1.05 - 5.17 |
| Beta | 0.42 |
About ACRS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACRS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
+11.02%
Aclaris Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
-2.65%
Aclaris shares are trading higher after the company announced FDA clearance of its IND application for a Phase 1A/1B trial of ATI-052.
